Indication

 Sotyktu So, have you found it? Logo and celebrity plaque psoriasis patient advocates Mindy Kaling and Ted Danson

Moderate to severe plaque psoriasis may be a big part of your life, but it doesn’t have to define you.

Mindy Kaling, actor, writer/producer, and an ally for those with plaque psoriasis, joins Ted Danson, actor and plaque psoriasis patient, in celebrating the unique inner vibe of people living with the condition. Watch below to see how Ted and Mindy are encouraging patients to talk to their dermatologists and find a treatment that is right for them.

Ted and Mindy are Bristol Myers Squibb partners. Ted has plaque psoriasis; Mindy does not. Ted and Mindy are not taking SOTYKTU.

HONOR YOUR “IT”

With Ted, Mindy, Emily, & Dr. Soung

Mindy Kaling, Ted Danson, and dermatologist Dr. Soung discuss plaque psoriasis and the importance of self-advocacy when talking to your doctor.

Dr. Soung has been compensated for her time.

Mindy Kaling, Ted Danson, and Dr Soung discuss SOTYKTU® and the importance of self advocacy for patients with plaque psoriasis

Dr. Soung has been compensated for her time.

After understanding more about plaque psoriasis, I am excited to collaborate with Ted on a topic so close to him and to support and empower others to take action.

Mindy Kaling

Ted Danson and SOTYKTU patient Emily discuss living with moderate to severe plaque psoriasis, focusing on personal stories of resilience and self-advocacy.

Emily is a real patient currently taking SOTYKTU and has been compensated for her time.

Ted Danson interviews SOTYKTU® patient Emily about living with moderate to severe plaque psoriasis

Emily is a real patient currently taking SOTYKTU and has been compensated for her time.

Psoriasis is an unscripted part of my life’s storyline. It’s not always comfortable, but it’s part of me. Through ‘SO, Have You Found It?’, I’m spotlighting the steps you can take to navigate this condition and celebrating the unique journeys of individuals managing plaque psoriasis.

Ted Danson

A PATH TO SELF-EMPOWERMENT

Your experience with moderate to severe plaque psoriasis is as unique as you are. 
Here are some ways to be a self-advocate:

Have candid conversations with your dermatologist about your condition

For more facts and resources to help inform those conversations, see below or visit sotyktu.com

Connect with others and find strength in shared experiences through support groups

Explore treatment options, like SOTYKTU, with your dermatologist

 Emily, a SOTYKTU® (deucravacitinib) patient living with moderate to severe plaque psoriasis

Rethinking treatment for your moderate to severe plaque psoriasis?

Everyone’s experience is different, and a conversation with your dermatologist is the first step toward finding out if SOTYKTU, an FDA-approved medicine for adults with moderate to severe plaque psoriasis, is right for you.

Some facts to know when talking to your doctor:

Clearer skin at 16 weeks

In one study, half of people taking SOTYKTU saw CLEAR OR ALMOST CLEAR SKIN at Week 16 vs 9% taking placebo.

In the same study, skin clearance was also measured in a different way, where a majority of people taking SOTYKTU saw 75% CLEARER SKIN at 16 weeks vs those taking placebo (53% vs 9%).

In two studies of moderate to severe plaque psoriasis, SOTYKTU was compared to placebo and Otezla® (apremilast). Of the 1684 adults in the studies, 841 received SOTYKTU, 421 received placebo, and 422 received Otezla. Patients were assessed at 16, 24, and 52 weeks after starting treatment.

Your results may vary.

SOTYKTU is the better pill for clearer skin

In one study, nearly TWICE AS MANY PEOPLE found 90% CLEARER SKIN with SOTYKTU vs Otezla
 42% of patients found 90% clearer skin after taking once-daily SOTYKTU® versus 22% of patients who found 90% clearer skin after taking twice-daily OTEZLA®.

AT 24 WEEKS. In one study, 42% of people taking SOTYKTU saw 90% clearer skin vs 22% taking Otezla.

In a second study, 32% of people taking SOTYKTU saw 90% clearer skin vs 20% taking Otezla.

Your results may vary.

Please see the most common side effects and other important safety information for SOTYKTU.

SOTYKTU® (deucravacitinib) 6mg once-daily pill for patients living with moderate to severe plaque psoriasis

SOTYKTU is the first of its kind once-daily pill*

It can be taken wherever you are, with or without food and at any time that fits your schedule best.

*Selective TYK2 inhibitor.

There's only one SOTYKTU, so ask for it by name. (Just say "soh-TIK-too.")

Learn more about SOTYKTU and find resources for discussing treatment with your dermatologist

GET TO KNOW SOTYKTU BROCHURE

An introduction to SOTYKTU featuring trial results, safety information, how it works, and more.


DOCTOR DISCUSSION GUIDE

Make your next dermatologist appointment your best one yet with this guide. It’s perfect for jotting down notes before, during, or after a chat with your doctor.

SKIN CLEARANCE RESULTS

Take a look at the efficacy results of SOTYKTU.

SAFETY INFORMATION

Explore the safety data for SOTYKTU.

RESOURCES AND SUPPORT

Whether you’re considering SOTYKTU and want to know what’s available to you or you’ve started on SOTYKTU and are interested in support materials that may help you along your treatment path, look here for downloadable resources and information to help.



Bristol Myers Squibb corporate website

SOTYKTU, SOTYKTU 360 SUPPORT, and SOTYKTU logo are trademarks of Bristol-Myers Squibb Company.
All other trademarks are property of their respective owners.
© 2024 Bristol-Myers Squibb Company.

This website is intended for U.S. residents 18 years of age or older.

1787-US-2400611 12/24